Part II: Pharmacokinetics and Clinical Pharmacology
First Statement of Responsibility
edited by Kurt Greeff.
.PUBLICATION, DISTRIBUTION, ETC
Place of Publication, Distribution, etc.
Berlin, Heidelberg
Name of Publisher, Distributor, etc.
Springer Berlin Heidelberg
Date of Publication, Distribution, etc.
1981
PHYSICAL DESCRIPTION
Specific Material Designation and Extent of Item
(xxi, 394 pages 64 illustrations)
SERIES
Series Title
Handbook of Experimental Pharmacology, Continuation of Handbuch der experimentellen Pharmakologie, 56 / 2.
CONTENTS NOTE
Text of Note
Pharmacokinetics --;Distribution, Metabolism, and Elimination --;1 Pharmacokinetics of Digitoxin --;2 Pharmacokinetics of Digoxin and Derivatives --;3 Pharmacokinetics of Strophanthus Glycosides --;4 Pharmacokinetics of Squill Glycosides --;Pharmacokinetics --;Additional Pharmacokinetic Parameters of Cardiac Glycosides --;5 Plasma Protein Binding of Cardiac Glycosides --;6 Intestinal Absorption and Secretion of Cardiac Glycosides --;7 Cardiac Uptake and Binding of Cardiac Glycosides --;8 Bioavailability of Cardiac Glycosides --;9 Pharmaceutical Quality Control Standards for Cardiac Glycosides --;Clinical Pharmacology --;10 Effects of Cardiac Glycosides on the Failing and Nonfailing Heart --;11 The Effect of Disease on Cardiac Glycoside Pharmacokinetics --;12 Clinical Indications and Choice of Cardiac Glycosides, Clinical Conditions Influencing Glycoside Effects --;13 Side Effects and Intoxication of Cardiac Glycosides: Manifestations and Treatment --;14 Interactions Between Cardiac Glycosides and Other Substances in the Body --;Author Index.
SUMMARY OR ABSTRACT
Text of Note
(1970) determined an elimination half-life of 14 h in normals as com- pared to 60 h in anuric patients. They found a half-life value of 18 h in healthy individuals as compared to 68 h in anuric patients. The findings clearly in- dicate that the elimination half-life of strophanthin is prolonged in renal failure.